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Abstract
Background: Anaemia is a common complication of patients with antineutrophil cytoplasmic antibody (ANCA)-
associated renal vasculitis. Nevertheless, the cause and degree of such cases of anaemia have not been elucidated
in detail. We aimed to investigate the prevalence, cause, pathogenesis of anaemia and the impact of anaemia on
prognosis in patients with ANCA-associated renal vasculitis.
Methods: We identified 45 patients with ANCA-associated renal vasculitis that were clinically and/or histologically
diagnosed and treated from 2003 to 2014 at University of Tsukuba Hospital. The relationships between anaemia
and various clinicopathological findings were evaluated.
Results: At the time of diagnosis of ANCA-associated renal vasculitis, all patients showed anaemia, with a mean
haemoglobin level of 7.5 ± 1.3 g/dL. Renal anaemia was diagnosed in 92% of patients, anaemia of chronic disease
(ACD) in 56%, and anaemia due to hemorrhage in 20%. Next, the patients were divided into two groups according
to anaemia severity: minimum haemoglobin (min Hb) < 7.5 (n = 24) and min Hb ≥ 7.5 (n = 21). A comparison of
baseline characteristics showed that serum albumin, maximum serum creatinine, minimum estimated glomerular
filtration rate (eGFR), serum cystatin C, and the area of tubulointerstitial damage were significantly different
between the haemoglobin groups (p < 0.05). No significant intergroup differences were observed in iron-related or
inflammation-related data. With regard to the relationship between anaemia severity and prognosis, patients in the
min Hb < 7.5 group tended to have a lower eGFR. Anaemia severity was associated with markedly lower survival
(Log-rank test, p = 0.03).
Conclusions: In this cohort of patients with ANCA-associated renal vasculitis, all subjects exhibited anaemia. In
regard to the cause and pathogenesis, the most prevalent form of anaemia was renal anaemia, not ACD, and a
potential reason for the high prevalence of anaemia in our cohort may have been the interaction between renal
anaemia and ACD. Moreover, anaemia severity was significantly associated with the degree of renal dysfunction
and life prognosis.
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Background
Antineutrophil cytoplasmic antibody (ANCA)-associ-
ated renal vasculitis is a systemic autoimmune disease
characterized by pauci-immune-type necrotizing small-
vessel vasculitis; vessels in the kidney, skin, respiratory
tract, gastrointestinal tract, and peripheral nerves are
often involved. Patients with ANCA-associated renal
vasculitis may present with a variety of clinical manifes-
tations, such as fatigue, fever, and weight loss [1].
Although routine laboratory tests are generally nonspe-
cific for ANCA-associated renal vasculitis, common
laboratory findings in ANCA-associated renal vasculitis
include leukocytosis, thrombocytosis, normochromic
and normocytic anaemia, and the elevation of acute-
phase inflammatory proteins. For example, a previous
study reported that anaemia was seen in 73% of
patients with granulomatosis with polyangiitis (GPA)
and the mean haemoglobin was 11.1 g/dL (range, 5.0–
15.1 g/dL) before treatment initiation [2]. In another
study, 14/36 (39%) of GPA patients with remission
status presented with anaemia, and the mean haemo-
globin was 13.0 ± 2.1 g/dl [3]. Thus, anaemia is known
to be a common complication of patients with ANCA-
associated renal vasculitis.
Anaemia has also been reported as a complication in
other autoimmune inflammatory diseases, such as
rheumatoid arthritis [4], inflammatory bowel disease [5,
6] and systemic lupus erythematosus (SLE) [7].
Anaemia that occurs as a complication in these diseases
is generally known as anaemia of chronic disease (ACD;
also called anaemia of inflammation) [8]. The mecha-
nisms of ACD are thought to be hepcidin-induced
changes in iron metabolism, inadequate response of
erythropoiesis, and shortening of the erythrocyte life-
span. A number of serious conditions are associated
with ACD, including infections, malignancies, auto-
immune diseases, chronic rejection after transplant-
ation, and chronic kidney disease (CKD). ACD is
automatically presumed to be complicated with ANCA-
associated renal vasculitis, and the causes of anaemia
with ANCA-associated renal vasculitis are expected to
be multifactorial. These causes can include renal
dysfunction, alveolar haemorrhage, malnutrition, the
use of immunosuppressive drugs, frequent in-hospital
phlebotomies and iron deficiency. However, the associ-
ations among these factors and the severity of anaemia
in patients with ANCA-associated renal vasculitis have
not been elucidated in detail. Moreover, almost all
previous studies of anaemia in association with other
autoimmune inflammatory diseases excluded patients
with renal dysfunction. Therefore, the pathogenesis and
severity of anaemia in patients with ANCA-associated
renal vasculitis may differ from those of anaemia in
patients with other autoimmune inflammatory diseases.
In general, anaemia in elderly patients is closely associ-
ated with various poor outcomes such as hospitalization
and mortality [9]. In patients with heart failure, anaemia
is associated with increased mortality [10]. Additionally,
in patients with CKD, several studies have demonstrated
that anaemia is closely related to mortality and the
progression of renal failure [11, 12]. Therefore, the
combination of severe anaemia and ANCA-associated
renal vasculitis may lead to poor renal prognosis and
shortened lifespan.
In the present study, we aimed to investigate the
prevalence and pathogenesis of anaemia in patients with
ANCA-associated renal vasculitis. We also evaluated the
pathological findings and the impact of anaemia on the
renal and life prognoses of the patients.
Methods
Study population
We identified 45 patients with ANCA-associated renal
vasculitis who had been clinically and/or histologically
diagnosed and treated from 2003 to 2014 at University
of Tsukuba Hospital. We recorded the demographic,
clinical and pathological features of these cases as well
as the treatments, patient survival rates and renal out-
comes. This research complied with the Declaration of
Helsinki and was approved by the Ethics Committee of
University of Tsukuba Hospital (H20–273, H24–169 and
H26–175). All participants provided informed consent
to participate in the study as required by the Institu-
tional Review Board (H20–273). An announcement of
this study was simultaneously posted at the outpatient
clinic of our institute.
Definition of anaemia
According to the World Health Organization, anaemia is
defined by haemoglobin levels lower than 13.0 g/dL for
men and 12.0 g/dL for women [13]. Renal anaemia is
defined as the presence of anaemia in association with a
relatively low erythropoietin concentration (< 50 mIU/
mL) or with a low estimated glomerular filtration rate
(eGFR) (< 30 min/mL/1.73 m2) but without an increase
in the reticulocyte count (< 10 × 104 /μL) [14, 15]. The
definition of ACD requires a low transferrin saturation
(< 16%) with a normal or increased serum ferritin
concentration (>100 ng/mL). Iron-deficiency anaemia is
characterized by the presence of anaemia in association
with low serum ferritin (< 10 ng/mL for females, < 15 ng/
mL for males) or with a transferrin saturation of less than
16% together with a serum ferritin level of less than 30 ng/
mL. The combination of iron-deficiency anaemia and ACD
is characterized by a transferrin saturation of less than 16%
and a serum ferritin between 30 and 100 ng/mL inclusive
[6, 8]. Moreover, in the present study, we evaluated the
serum hepcidin-25 concentration to use as a reference
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value for ACD. The serum hepcidin-25 concentration was
measured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (product No. S-1337;
Peninsula Laboratories, Bachem, CA). This ELISA system
was used in a number of previous studies [16, 17]. If
patients had additional cytopenia (white blood cell count <
4000/μL, platelet count < 10 × 104/μL) and/or abnormal
white blood cell differentiation, haematological abnormal-
ities were suspected and we added a haematological exam-
ination, including bone marrow aspiration. Haemolysis was
diagnosed if the lactate dehydrogenase level was greater
than 500 IU/L without the elevation of another liver
enzyme or if the haptoglobin level was less than 10 mg/dL.
Vitamin B12 deficiency was diagnosed if the serum vitamin
B12 concentration was less than 200 pg/mL, and folate
deficiency was diagnosed if the serum folate level was less
than 3.6 ng/mL.
Pathologic analysis
Renal biopsy specimens were routinely assessed by light mi-
croscopy, immunofluorescence, and electron microscopy.
An expert renal pathologist made the diagnoses according
to the international histological classification [18]. The area
of tubulointerstitial damage was semi-quantitatively evalu-
ated in renal cortical tissue [19–21].
Statistical analysis
The laboratory examination results were summarized in
the form of percentages, means ± standard deviations (SD),
or medians with ranges. To perform statistical comparisons,
we used the chi-squared test for categorical variables and
Student’s t-test or the Mann-Whitney U test for continuous
variables. The cumulative survival and renal survival were
estimated using the Kaplan-Meier method and compared
among the groups using the log-rank test. A p value < 0.05
was considered statistically significant in all analyses. The
IBM SPSS software package, ver. 22, was used.
Results
Patient characteristics at diagnosis
The patient characteristics at diagnosis are shown in
Table 1. Of the 45 patients, 20 (44%) were men. The
Table 1 Clinicopathological findings of patients with ANCA-associated renal vasculitis in each anaemia severity group
Variable All patients Min Hb <7.5 Min Hb ≥7.5 P Value
Patient number 45 24 21
Gender male:female 20:25 12:12 8:13 0.42
Age (years) 71 ± 7.8 (47–82) 72 ± 7.0 (54–82) 70 ± 8.7 (47–82) 0.36
Birmingham vasculitis activity score 20 (12–39) 19 (12–36) 20 (12–39) 0.58
Haemoglobin on admission (g/dL) 9.0 ± 1.6 8.1 ± 1.1 10.1 ± 1.3 <0.001
Minimum haemoglobin (g/dL) 7.5 ± 1.3 6.5 ± 0.6 8.7 ± 0.9 <0.001
MCV (fL) 90 ± 6.2 88 ± 6.8 91 ± 5.1 0.18
MCH (pg) 29.5 ± 2.4 29.1 ± 2.6 30.0 ± 2.2 0.21
MCHC (%) 33.0 ± 1.2 32.9 ± 0.9 33.0 ± 1.3 0.76
Reticulocyte count (×104/μL) 4.65 ± 2.50 4.23 ± 2.47 5.09 ± 2.54 0.35
Serum erythropoietin (mIU/mL) 15.1 (5.8–105) 17.5 (5.8–105) 14.5 (11–36.6) 0.43
Transferrin saturation (%) 14.7 (4.2–80.2) 12.8 (4.2–80.2) 17.5 (9.7–54.5) 0.18
Serum ferritin (ng/mL) 322 (46.9–2231) 382 (46.9–1839) 291 (94.9–2231) 0.21
Serum c-reactive protein (mg/dL) 6.8 (0.03–24.5) 7.9 (0.43–24.5) 5.0 (0.03–17.3) 0.09
Serum hepcidin-25 (ng/mL) 71.5 (10.5–463) 74.9 (45.9–463) 37 (10.5–363) 0.28
Serum albumin (g/dL) 2.6 ± 0.8 2.3 ± 0.6 2.9 ± 0.8 0.004
Serum creatinine on admission (mg/dL) 2.5 (1.0–10.8 2.9 (1.0–10.8) 2.3 (1.0–6.3) 0.06
Maximum serum creatinine (mg/dL) 3.2 (1.0–11.7) 4.4 (1.1–11.7) 2.4 (1.0–7.2) 0.01
eGFR on admission (mL/min/1.73 m2) 19.5 (4.2–54.2) 13.8 (4.2–44.6) 21.6 (7.0–54.2) 0.09
Minimum eGFR (mL/min/1.73 m2) 15.3 (3.9–54.2) 8.9 (3.9–39.2) 19.0 (4.8–54.2) 0.01
Blood urea nitrogen (mg/dL) 34.5 (13–101) 36.9 (13–101) 30.9 (18.3–62) 0.09
Serum cystatin c (mg/L) 2.8 ± 0.9 3.2 ± 0.9 2.2 ± 0.6 0.02
Number of renal biopsy, n (%) 33 (73) 13 (54) 20 (95) 0.00
Area of tubulointerstitial damage (%) 55 ± 21 65 ± 18 48 ± 20 0.048
Values are shown as the numbers of patients, the median (range) or the mean ± SD. Abbreviations: Min Hb Minimum haemoglobin, MCV Mean corpuscular volume,
MCH Mean corpuscular haemoglobin, MCHC Mean corpuscular haemoglobin concentration, eGFR Estimated glomerular filtration rate
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mean age at diagnosis was 71 ± 7.8 years. Two patients
already had renal dysfunction and 8 patients showed
mild anaemia (haemoglobin 10.1–12.9 g/dL) before the
disease onset. Eighteen patients had a history of hyper-
tension, 2 had a history of diabetes, 3 had a history of
cardiovascular disease, 4 had a history of malignancy,
and 1 patient had a history of rheumatoid arthritis. In
this cohort, the median follow-up duration was
42 months (range, 0–123 months). All patients were
myeloperoxidase-ANCA single-positive. With respect to
the vasculitis disease classification, physicians diagnosed
microscopic polyangiitis in 43 patients, eosinophilic
granulomatosis with polyangiitis in 1 patient, and GPA
in 1 patient. The median Birmingham Vasculitis Activity
Score was 20. The mean haemoglobin on admission was
9.0 g/dL, and the mean minimum haemoglobin (min
Hb) was 7.5 g/dL. The median serum erythropoietin was
15.1 mIU/mL (based on measurement in 25 patients),
the median serum ferritin was 322 ng/mL, the median
serum c-reactive protein was 6.8 mg/dL, the median
serum hepcidin-25 was 71.5 ng/mL (based on measure-
ment in 15 patients) and the median minimum eGFR
was 15.3 mL/min/1.73 m2 (range, 3.9–54.2 mL/min/
1.73 m2). All patients had renal involvement, and 33
patients (73%) had undergone renal biopsy. Using the
international histological classification [18], we identified
8 patients in the Focal class, 12 in the Crescentic class, 7
in the Mixed class, and 2 in the Sclerotic class. In 4
patients, the renal biopsy specimens were inadequate for
pathological diagnosis. The mean area of tubulointersti-
tial damage was 55%. Twenty-three patients (51%) had
pulmonary involvement, including 20 with interstitial
pneumonia, 5 with alveolar haemorrhage, and 2 with
pulmonary granuloma.
Prevalence and pathogenesis of anaemia with ANCA-
associated renal vasculitis.
In this study, we focused on the relationship between
ANCA-associated renal vasculitis and anaemia. At the
time of the diagnosis of ANCA-associated renal vascu-
litis, all patients showed anaemia (the haemoglobin on
admission was 9.0 ± 1.6 g/dL and the min Hb was 7.5 ±
1.3 g/dL). Age and gender had no significant influence
on the severity of anaemia. The causes of anaemia are
summarized in Fig. 1. Renal anaemia was diagnosed in
35 of 38 (92%) patients, ACD was diagnosed in 20 of 36
(56%) patients (one patient was diagnosed with iron-
deficiency anaemia-associated ACD), and anaemia due
to haemorrhage was diagnosed in 9 of 45 (20%) patients.
No patients were suspected to exhibit haematological
abnormalities or haemolysis. Vitamin B12 deficiency was
diagnosed in 1 of 15 (7%) patients, and folate deficiency
was diagnosed in 6 of 11 (55%) patients. However, none
of the patients exhibited macrocytic anaemia, and none
required vitamin B12 or folate supplementation. There-
fore, we considered that vitamin B12 and folate defi-
ciency did not greatly affect the anaemia severity.
Comparison of backgrounds and prognosis according to
anaemia severity
Next, we investigated the features of the patients that
were influenced by the anaemia severity. The patients
were divided into two groups according to their min Hb
values: a group with min Hb < 7.5 (n = 24) and a group
with min Hb ≥ 7.5 (n = 21) (Table 1). A comparison of
the baseline characteristics showed that serum albumin,
maximum serum creatinine, minimum eGFR, serum
cystatin C, and the area of tubulointerstitial damage
were significantly different between the two groups. No
significant intergroup differences were observed in iron-
related data such as transferrin saturation and serum
ferritin, or in inflammation-related data such as serum fer-
ritin, serum c-reactive protein, and serum hepcidin-25.
Next, a comparison of the treatments and progno-
ses is shown in Table 2. Not surprisingly, the transfu-
sion of red blood cells and the use of erythropoiesis-
stimulating agents (ESAs) were more frequent in the
min Hb < 7.5 group than the min Hb ≥ 7.5 group. Of
the treatments used for ANCA-associated renal
vasculitis, plasma exchange therapy was chosen
significantly more often in the min Hb < 7.5 group
than in the min Hb ≥ 7.5 group. The indication for
plasma exchange therapy in these 6 patients was
alveolar haemorrhage in 3 patients and severe renal
involvement in 3 patients. Three out of 5 patients with
alveolar haemorrhage were treated with plasma exchange.
One of the remaining 2 patients was not treated with
plasma exchange because the alveolar haemorrhage was
considered to be resolved. Although we reviewed the rele-
vant medical records, we could not determine why the
other patient was treated without plasma exchange. By
contrast, the rates of treatment with steroid pulse therapy
and of treatment using cyclophosphamide at 4 and
Fig. 1 The causes of anaemia in patients with ANCA-associated renal
vasculitis. Abbreviation: ACD, anaemia of chronic disease
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12 weeks after treatment initiation were similar between
the two groups.
Finally, we examined the relationship between the
severity of anaemia and prognosis (Table 2). There was
no significant difference in the duration of hospita-
lization. However, all 4 patients who died during the first
hospitalization were in the min Hb < 7.5 group. Over the
course of the follow-up, 11 of 45 (24%) patients died,
and 2 of 45 (4%) patients developed end-stage kidney
disease. Figures 2 and 3 show the temporal changes in
the haemoglobin concentration and eGFR levels. The
haemoglobin concentration showed significant diffe-
rences between the groups upon admission, at the time
of min Hb, after 2 weeks, and after 48 weeks. There is a
possibility that severe anaemia at diagnosis was pro-
longed for at least 1 year after the diagnosis. On the
other hand, eGFR showed significant differences
between the groups at the time of minimum eGFR, and
the min Hb < 7.5 group tended to have a lower eGFR.
As shown in the survival curve estimated using the
Kaplan-Meier method (Fig. 4), increased anaemia sever-
ity was associated with a markedly lower survival rate.
Discussion
In the present study, we focused on the physiological
impact of anaemia in cases of ANCA-associated renal
vasculitis. All ANCA-associated renal vasculitis patients
in this cohort were found to have anaemia, and the
causes of anaemia in our patients were expected to be
multifactorial, with renal anaemia being the predomin-
ant type. Also, the severity of anaemia was closely asso-
ciated with renal function, but not with the iron-related
or inflammation-related findings. Moreover, anaemia
severity was a factor affecting the renal and life progno-
ses of ANCA-associated renal vasculitis patients.
Before discussing our findings, we should first consider
the previous studies on anaemia in patients with other
Table 2 Comparison of treatments and prognoses
All patients Min Hb <7.5 Min Hb ≥7.5 P Value
Treatment
Blood transfusion of RBC, n (%) 13 (29) 12 (50) 1 (5) 0.001
Use of ESAs, n (%) 20 (44) 16 (67) 4 (19) 0.001
Plasma exchange therapy, n (%) 6 (13) 6 (25) 0 (0) 0.01
Steroid pulse therapy, n (%) 20 (44) 13 (54) 7 (33) 0.16
Use of CY within 4 weeks after treatment initiation, n (%) 1 (2) 1 (4) 0 (0) 0.33
Use of CY within 12 weeks after treatment initiation, n (%) 14 (35) 9 (47) 5 (24) 0.12
Prognosis
Duration of hospitalization (days) 70 ± 26 75 ± 28 65 ± 23 0.23
Number of deaths during the first hospitalization, n (%) 4 (9) 4 (17) 0 (0) 0.05
Number of deaths at last follow-up, n (%) 11 (24) 8 (33) 3(14) 0.14
Number of patients with end-stage kidney disease at last follow-up, n (%) 2 (4) 2 (8) 0 (0) 0.18
Values are shown as the numbers of patients or the mean ± SD. Abbreviations: Min Hb Minimum haemoglobin, RBC Red blood cell, ESAs Erythropoiesis-stimulating
agents, CY Cyclophosphamide
Fig. 2 Temporal changes of haemoglobin in each anaemia severity
group. Values are shown as the mean ± SD. *p < 0.05. Abbreviation:
Min Hb, minimum haemoglobin
Fig. 3 Temporal changes of eGFR in each anaemia severity group.
Values are shown as the mean ± SD. *p < 0.05. Abbreviations:
Min Hb, minimum haemoglobin; eGFR, estimated glomerular
filtration rate
Kawamura et al. BMC Nephrology  (2017) 18:337 Page 5 of 8
autoimmune inflammatory diseases. The previous stud-
ies reported that the prevalence of anaemia was 33–59%
in patients with rheumatoid arthritis [4], 20–68% in
those with inflammatory bowel disease [5] and 38% in
those with SLE [7]. According to these studies, the
causes of anaemia were multifactorial, and the main
cause was ACD. In comparison, we found that anaemia
was more frequent in patients with ANCA-associated
renal vasculitis, and the causes of anaemia with ANCA-
associated renal vasculitis were multifactorial, just as for
anaemia with other autoimmune inflammatory diseases.
However, the most prevalent cause was renal anaemia,
not ACD. More than 90% of our patients had renal
anaemia, while approximately half of the patients had
ACD. A possible reason for the high prevalence of
anaemia in our patients with ANCA-associated renal
vasculitis may have been the interaction between renal
anaemia and ACD. As described above, renal dysfunc-
tion is an important cause of ACD [8]. By contrast,
inflammation is an essential cause of renal anaemia [22].
Both renal anaemia and ACD are mediated through the
effects of inflammatory cytokines such as interleukin
(IL)-1, IL-6, and tumour necrosis factor-alpha. There-
fore, in this study, we suspected that hepcidin played a
key role in the interaction between renal anaemia and
ACD. Hepcidin is an acute-phase protein, which is
mainly produced in the liver and secreted into the circu-
lation. Hepcidin is the main regulator of iron metabol-
ism, and its production is regulated by changes in the
body’s iron stores, inflammation, erythropoietic activity,
and hypoxia [23]. It has been reported that the hepcidin
level is increased in CKD patients, possibly due to
increased production and/or reduced renal clearance
[24, 25]. Hepcidin is also an acute-phase reactant
induced by inflammation. We therefore expected the
hepcidin concentration to be increased in our patients
with ANCA-associated renal vasculitis due to both renal
dysfunction and inflammation. However, in this cohort,
the hepcidin-25 concentration was not significantly
related to anaemia severity, renal dysfunction, or other
inflammatory findings. In patients with ANCA-
associated renal vasculitis, there may be a more complex
relationship among various factors that influence hepci-
din levels, including iron, inflammation, reduced renal
clearance, and anaemia severity [26]. Additionally, the
measurement of the serum hepcidin-25 concentration
was performed in only a limited number of patients.
Next, we addressed the reason for the high prevalence
of renal anaemia and the influence of renal anaemia on
the severity of anaemia in our patients with ANCA-
associated renal vasculitis. McClellan et al. [15] reported
that the prevalence of anaemia increased as the level of
kidney function decreased. For example, the percentage
of patients with haemoglobin ≤12 g/dL increased from
26.7% to 75.5% as the glomerular filtration rate
decreased from ≥ 60 mL/min/1.73 m2 to < 15 mL/min/
1.73 m2. In our cohort, all patients had renal involve-
ment, and the median eGFR was 15.3 mL/min/1.73 m2.
Therefore, advanced renal dysfunction with ANCA-
associated renal vasculitis corresponded to a high preva-
lence of renal anaemia and anaemia severity. We also
performed a review of the literature to examine how
renal anaemia affects anaemia severity in patients with
ANCA-associated vasculitis (Table 3). Several previous
studies have reported an association between renal dys-
function and anaemia severity. However, anaemia sever-
ity was relatively mild in the studies that included
patients without renal involvement—that is, in patients
with preserved renal function [2, 3, 27]. On the other
hand, anaemia severity was relatively advanced in the
ANCA-associated renal vasculitis cohorts [28–30].
Moreover, there may be a tendency for the severity of
anaemia to progress as the level of kidney function
decreases. As a result, we can conclude that the causes of
anaemia with ANCA-associated renal vasculitis are multi-
factorial, and that while renal anaemia is easily missed, it
is the most frequent and influential cause of anaemia in
patients with ANCA-associated renal vasculitis.
Next, we investigated the mechanism of renal anaemia
in ANCA-associated renal vasculitis patients. Our study
of the histopathological findings demonstrated that renal
interstitial damage is associated with anaemia severity.
Some recent studies investigated the association between
anaemia and biopsy-proven interstitial lesions of diabetic
nephropathy [19], or between anaemia and post-
transplant nephropathy [20]. Based on the findings of
these previous studies and our present investigation, it is
possible to propose several mechanisms by which inter-
stitial damage could influence anaemia. One such mech-
anism is a reduction in the production of erythropoietin
resulting from a decrease in erythropoietin-producing
cells due to interstitial damage. Recent basic science
Fig. 4 Comparison of the survival rate in each anaemia severity group.
Abbreviation: Min Hb, minimum haemoglobin
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studies have suggested that renal interstitial fibroblasts
produce erythropoietin in response to hypoxia or an-
aemia [31]. Therefore, the progression of interstitial
damage could lead to the development of anaemia,
resulting in erythropoietin deficiency. However, in this
study, there was no significant relationship between the
area of interstitial damage and the serum erythropoietin
concentration. Nonetheless, this discrepancy may be
attributable to study limitations. That is, we measured
the serum erythropoietin concentration only in a limited
number of patients. In addition, we could not perform
renal biopsies in all patients.
Whether anaemia with ANCA-associated renal vascu-
litis influences the renal and life prognoses must also be
addressed. As described above, several studies have dem-
onstrated that anaemia is a risk factor for shortened
lifespan and/or increased renal dysfunction [11, 12].
Similarly, the present data demonstrated that anaemia
severity was associated with life prognosis in our
patients with ANCA-associated renal vasculitis. On the
other hand, eGFR was also significantly different
between the groups at the time of minimum eGFR, and
the lower haemoglobin group tended to have a lower
eGFR. Therefore, our results underscore that the severity
of anaemia has an impact on renal and life prognoses. In
general, the administration of ESAs is beneficial in pa-
tients with renal anaemia [32, 33], and the use of ESAs
may be a treatment option for patients with ACD [8].
Unfortunately, although renal anaemia was diagnosed in
35 patients in this cohort, ESAs were used in only 16 of
the 35 (46%). There is a possibility that the treatment for
anaemia itself would lead to an improvement in the
prognosis of patients with ANCA-associated renal
vasculitis. In the future, therefore, it will be important to
investigate the efficacy of earlier treatment initiation for
anaemia, the optimal timing of anaemia intervention
and the effectiveness of ESAs therapy.
Finally, our study has several limitations. First, this
study was a retrospective investigation of a small cohort
at a single centre, and our results therefore cannot be
generalized without further investigation. Second, when
our patients with ANCA-associated renal vasculitis had
both renal anaemia and ACD, it was difficult to clearly
distinguish between them. Third, as described above, we
could not analyse patients with ANCA-associated vascu-
litis without renal involvement. Despite these limitations,
the present study provided the first investigation of the
pathogenesis of anaemia with ANCA-associated renal
vasculitis and the impact of anaemia on prognosis. It is
hoped that our findings will inspire additional research
in a larger cohort.
Conclusions
We demonstrated a high prevalence of anaemia in a
cohort of patients with ANCA-associated renal vasculitis.
A possible reason for the high prevalence of anaemia in
these patients was the interaction between renal anaemia
and ACD. The severity of anaemia was associated with the
degree of renal dysfunction and life prognosis.
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crescentic glomerulonephritis
(eGFR 40.6 ± 21.4
ml/min/1.73 m2)
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